Skip to main content
SpringerLink
Log in

Journal club: Recent therapeutic developments in the management of chronic spontaneous urticaria

  • Residents’ Corner
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lee SJ, Ha EK, Jee HM, et al. Prevalence and risk factors of urticaria with a focus on chronic urticaria in children. Allergy Asthma Immunol Res 2017; 9: 212–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers 2022; 8: 61.

    Article  PubMed  Google Scholar 

  3. Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum (CIA) update 2020. Int Arch Allergy Immunol 2020; 181: 321–33.

    Article  CAS  PubMed  Google Scholar 

  4. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, Guillén-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 1153–65.

    Article  PubMed  Google Scholar 

  5. Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old. Allergy 2022; 77: 17–38.

    Article  CAS  PubMed  Google Scholar 

  6. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77: 734–66.

    Article  PubMed  Google Scholar 

  7. Terhorst-Molawi D, Fox L, Siebenhaar F, Metz M, Maurer M. Stepping down treatment in chronic spontaneous urticaria: what we know and what we don’t know. Am J Clin Dermatol 2023; 24: 397–404.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128: 567–73.e1.

    Article  CAS  PubMed  Google Scholar 

  9. Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract 2021; 9: 1067–78.

    Article  CAS  PubMed  Google Scholar 

  10. Ferrer M, Boccon-Gibod I, Gonçalo M, et al. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria. Eur J Dermatol EJD 2017; 27: 455–63.

    Article  CAS  PubMed  Google Scholar 

  11. Kocatürk E, Zuberbier T. New biologics in the treatment of urticaria. Curr Opin Allergy Clin Immunol 2018; 18: 425–31.

    Article  PubMed  Google Scholar 

  12. Türk M, Maurer M, Yılmaz İ. How to discontinue omalizumab in chronic spontaneous urticaria? Allergy 2019; 74: 821–4.

    Article  PubMed  Google Scholar 

  13. Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract 2020; 8: 113–24.

    Article  PubMed  Google Scholar 

  14. Wang J, He L, Yi W, et al. Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria. Clin Immunol Orlando Fla 2023; 247: 109247.

    Article  CAS  Google Scholar 

  15. Kolkhir P, Altrichter S, Asero R, et al. Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria. Allergy Asthma Immunol Res 2021; 13: 545–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review. Allergy 2017; 72: 1440–60.

    Article  CAS  PubMed  Google Scholar 

  17. Yuan Y, Kolios AGA, Liu Y, et al. Therapeutic potential of interleukin-2 in autoimmune diseases. Trends Mol Med 2022; 28: 596–612.

    Article  CAS  PubMed  Google Scholar 

  18. He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med 2016; 22: 991–3.

    Article  CAS  PubMed  Google Scholar 

  19. He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2020; 79: 141–9.

    Article  CAS  PubMed  Google Scholar 

  20. Le Duff F, Bouaziz JD, Fontas E, et al. Low-dose IL-2 for treating moderate to severe alopecia areata: a 52-week multicenter prospective placebo-controlled study assessing its impact on t regulatory cell and nk cell populations. J Invest Dermatol 2021; 141: 933–6.e6.

    Article  Google Scholar 

  21. Long H, Liao J, Yang M, Wang X, Zhang G, Lu Q. Low-dose interleukin-2: a potential treatment for pemphigus vulgaris. Autoimmun Rev 2021; 20: 102906.

    Article  CAS  PubMed  Google Scholar 

  22. Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D. Benralizumab for chronic spontaneous urticaria. N Engl J Med 2020; 383: 1389–91.

    Article  PubMed  Google Scholar 

  23. Maul JT, Distler M, Kolios A, et al. Canakinumab lacks efficacy in treating adult patients with moderate to severe chronic spontaneous urticaria in a phase II randomized double-blind placebo-controlled single-center study. J Allergy Clin Immunol Pract 2021; 9: 463–8.e3.

    Article  CAS  PubMed  Google Scholar 

  24. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 2012; 135: 327–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Altrichter S, Staubach P, Pasha M, et al. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J Allergy Clin Immunol 2022; 149: 1683–90.e7.

    Article  CAS  PubMed  Google Scholar 

  26. Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (Spontaneous) urticaria: a meta-analysis of « Real-world » evidence. JAMA Dermatol 2019; 155: 29–38.

    Article  PubMed  Google Scholar 

  27. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med 2019; 381: 1321–32.

    Article  CAS  PubMed  Google Scholar 

  28. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014; 44: 1371–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Liang C, Tian D, Ren X, et al. The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur J Med Chem 2018; 151: 315–26.

    Article  CAS  PubMed  Google Scholar 

  30. Hata D, Kawakami Y, Inagaki N, et al. Involvement of Bruton’s tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med 1998; 187: 1235–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kneidinger M, Schmidt U, Rix U, et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008; 111: 3097–107.

    Article  CAS  PubMed  Google Scholar 

  32. Maurer M, Berger W, Giménez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol 2022; 150: 1498–506.e2.

    Article  CAS  PubMed  Google Scholar 

  33. Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol 2022; 32: 97–115.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Hôpital Edouard Herriot, Lyon, France

    Inès Chircop

  2. CIRI, Centre International de Recherche en Infectiologie, (Team Epidermal Immunity and Allergy); INSERM, U1111, Univ Lyon; Université de Lyon 1; École Normale Supérieure de Lyon; CNRS, UMR 5308, Lyon, France

    Inès Chircop & Victoire Reynaud

  3. Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal

    Ana Maria Lé

  4. Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany

    Tassilo Dege

  5. Department of Dermatology, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge, UK

    Niamh Byrne

  6. Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Paloma Garcia-Piqueras

  7. Department of Dermatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain

    Ángel Manuel Rosell-Díaz

  8. Department of Allergology and Immunology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France

    Victoire Reynaud

Authors
  1. Inès Chircop
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Maria Lé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tassilo Dege
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Niamh Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paloma Garcia-Piqueras
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ángel Manuel Rosell-Díaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Victoire Reynaud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Inès Chircop.

Ethics declarations

Conflict of interest: none.

Additional information

Financial support: none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chircop, I., Lé, A.M., Dege, T. et al. Journal club: Recent therapeutic developments in the management of chronic spontaneous urticaria. Eur J Dermatol 33, 326–329 (2023). https://doi.org/10.1684/ejd.2023.4506

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2023.4506

Search

Navigation